Pyxis Oncology (PYXS) Operating Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Operating Expenses data on file, last reported at $29.3 million in Q4 2025.

• On a quarterly basis, Operating Expenses fell 26.79% year-over-year to $29.3 million in Q4 2025; TTM through Dec 2025 was $98.3 million, a 6.94% decrease from a year earlier, with the FY2025 full-year figure at $98.3 million, down 6.94% from the prior year.
• Operating Expenses for Q4 2025 stood at $29.3 million, up from $23.5 million in the prior quarter.
• Over the last five years, Operating Expenses for PYXS reached as high as $40.1 million in Q4 2024 and fell as low as $5.9 million in Q2 2021.
• Historically, Operating Expenses has averaged $24.0 million across 5 years, with a median of $23.2 million in 2025.
• Across the five-year window, Operating Expenses soared 333.02% in 2022 and slumped 53.21% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $16.4 million in 2021, then jumped by 131.18% to $38.0 million in 2022, then slumped by 53.21% to $17.8 million in 2023, then jumped by 125.52% to $40.1 million in 2024, then retreated by 26.79% to $29.3 million in 2025.
• Per Business Quant data, the three most recent Operating Expenses figures were $29.3 million in Q4 2025, $23.5 million in Q3 2025, and $22.6 million in Q2 2025.